Yazar "Turgut, B." seçeneğine göre listele
Listeleniyor 1 - 13 / 13
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe DOES ANTI-TNF THERAPY CAUSE ANY CHANGE IN PLATELET ACTIVATION IN ANKYLOSING SPONDYLITIS PATIENTS?(Ferrata Storti Foundation, 2009) Pamuk, G. E.; Pamuk, Oe N.; Orum, H.; Turgut, B.; Demir, M.[Abstract Not Available]Öğe Increased adiponectin level in non-Hodgkin lymphoma and its relationship with interleukin-10.: Correlation with clinical features and outcome(Bmc, 2006) Pamuk, G. E.; Turgut, B.; Demir, M.; Vural, Oe.It was reported that interieukin-10 (IL-10) level increased in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) patients; moreover this was associated with poor prognosis. In addition, it was stated that adiponectin induced the antiinflammatory cytokine IL-10. We evaluated adiponectin and IL-10 levels in NHL and CLL patients. We included newly diagnosed 28 NHL, 23 CLL patients, and 17 healthy subjects. In NHL patients, adiponectin level was higher than in CLL group and controls (p values <0.05). In CLL group, IL-10 level was lower than in NHL, and control groups (p values <0.05). Adiponectin level had a positive correlation with IL-10 level in the NHL patients (r=0.41, p=0.04). In the NHL group, the median survival of patients with high IL-10 levels was shorter (22 months vs. not reached, p=0.03). Increased IL-10 levels helped to predict poor outcome in our NHL patients. High adiponectin levels and a relationship between adiponectin/IL-10 in newly diagnosed NHL patients might suggest a role for both in the immunodysregulation in NHL.Öğe INCREASED LEVELS OF PLATELET-LEUCOCYTE COMPLEXES IN BEHCET'S DISEASE PATIENTS WITH MAJOR VASCULAR INVOLVEMENT(Ferrata Storti Foundation, 2009) Pamuk, G. E.; Pamuk, Oe N.; Orum, H.; Demir, M.; Turgut, B.[Abstract Not Available]Öğe INVESTIGATION OF COGNITIVE DYSFUNCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE(Wiley-Blackwell, 2011) Buyukkoyuncu, N.; Turgut, N.; Altiay, G.; Demir, M.; Karadag, H.; Turgut, B.; Caglar, T.[Abstract Not Available]Öğe Is there any effect of obesity on thrombin activatable fibrinolysis inhibitor levels in postmenopausal women?(Elsevier Science Inc, 2009) Taskiran, B.; Guldiken, S.; Demir, M.; Kilic-Okman, T.; Arikan, E.; Turgut, B.; Tugrul, A.[Abstract Not Available]Öğe THE MANAGEMENT OF THYROTOXICOSIS BY THERAPEUTIC PLASMA EXCHANGE IN PATIENTS COMPLICATED WITH ANTITHYROID DRUGS(Editura Acad Romane, 2011) Sezer, A.; Guldiken, S.; Turgut, B.; Irfanoglu, M. E.Objective. Antithyroid drugs, surgical excision, and radiation therapy with I-131 are the common treatment modalities thyrotoxicosis. The medical treatment of thyrotoxicosis has approximately 0.35% serious complications which consist of agranulocytosis, liver necrosis and failure. Therapeutic plasma exchange is an effective preoperative preparation method in thyrotoxicosis patients who are candidates for surgery and unable to manage an euthyroid state with medical treatment. Patients and Methods. This study was constructed between 2002-2009 in 9 patients who were resistant or had complications with medical treatment of thyrotoxicosis. The therapeutic plasma exchange procedures were performed with discontinuous flow cell separator devices. Results. Seven patients were females and 2 patients were males. The mean age was 51.22 years (32-78 years). The mean duration of the disease was 35.4 months (3-120 months). The patients underwent 3.3 (2-6 sessions) session of therapeutic plasma exchange before surgery. The mean volume of plasma exchange was 10549 mL (7150-18372 mL). The plasma is exchanged with %10 albumin and/or fresh frozen plasma. The complication rate was 22% during therapeutic plasma exchange. Four patients underwent near total thyroidectomy and five patients underwent total thyroidectomy. The mortality rate was zero. Neck hematoma causing acute respiratory compromise and requiring urgent evacuation developed in one patient. Conclusions. Total plasma exchange is an effective and safe procedure in preoperative preparation of the patients with thyrotoxicosis who were resistant or complicated with antithyroid drug in which a high level of concern and steady supervision is mandatory to prevent life threatening preoperative and postoperative complications.Öğe Monitoring the peripheral blood lymphocyte subtypes in drug reaction with eosinophilia and systemic symptoms (DRESS)(Mosby-Elsevier, 2007) Yazicioglu, M.; Elmas, R.; Genchallacoglu, T.; Yildirim, S.; Turgut, B.[Abstract Not Available]Öğe Oxidative stress and antioxidant capacity in diabetic and non-diabetic acute ischemic stroke patients(Wiley-Blackwell, 2008) Guldiken, B.; Demir, M.; Guldiken, S.; Turgut, N.; Turgut, B.; Tugrul, A.[Abstract Not Available]Öğe Relationship between total anti-oxidant capacity, homocysteine levels and cognitive tests in patients with amyotrophic lateral sclerosis(Wiley-Blackwell, 2012) Kat, S.; Turgut, N.; Guldiken, B.; Demir, M.; Erbas, H.; Turgut, B.[Abstract Not Available]Öğe Secondary amyloidosis causing nephrotic syndrome in a patient with non-Hodgkin's lymphoma(Blackwell Publishing, 2006) Pamuk, G. E.; Demir, M.; Oeruem, H.; Turgut, B.; Oezyilmaz, F.; Tekguenduez, E.Secondary amyloidosis is usually a complication of chronic inflammation. Amyloidosis cases during the course of non-Hodgkin's lymphoma (NHL) are usually of AL-type, only one NHL patient with secondary amyloidosis has been reported. Our 79-year-old male patient visited us with multiple lymphadenopathies, and he was diagnosed with nodal marginal zone B-cell lymphoma. After four cycles of combined chemotherapy; his urea, creatinine levels started to increase and he developed nephrotic-range proteinuria. His rectal biopsy demonstrated amyloid deposition in submucosal vessel walls. The patient has been under hemodialysis for 10 months and his lymphoma is still in partial remission. We presented this case because it is the second NHL patient who developed secondary amyloidosis during his disease course.Öğe Serum soluble Fas ligand levels and peripheral blood lymphocyte subsets in patients with drug-induced maculopapular rashes, dress, and viral exanthemas(Elsevier Espana Slu, 2020) Yazicioglu, M.; Ozdemir, P. Gokmirza; Turgut, B.; Sut, N.Background: Fatty acid synthetase (Fas)/Fas ligand (FasL)-dependent apoptotic pathways have been reported as being involved in the pathogenesis of drug-induced maculopapular rashes. Objective: We investigated serum soluble FasL (sFasL) levels and peripheral blood lymphocyte subtypes to discriminate maculopapular drug eruptions (MPDE) from viral exanthema (VE). Patients/methods: Children with confirmed MPDE (group I), VE (group II), and drug rashes with eosinophilia and systemic symptoms (DRESS) or drug-induced hypersensitivity syndrome (DIHS) (group III) were included. Serum sFasL levels and peripheral blood lymphocyte subtypes were analyzed in groups I- III on admission, and repeated twice (only once for group IV-controls). Results: There were no significant serum soluble FasL level differences among the groups for all the samples. In the initial samples, CD19(+) cell numbers in group II were significantly higher than in group IV, and the CD4(+) /CD8(+) ratio was higher than groups I and IV. In the second samples, CD4(+) and CD19(+) cell numbers were significantly higher in group II than group I. In the final samples, CD4(+) cell numbers in group II were significantly higher than group I and group III. CD19(+) cells numbers in group III were significantly lower than the other groups for all samples. Conclusion: Serum sFasL levels were not found to be useful in discriminating viral exanthemas from other drug rashes. The significant differences between MPDE, VE, and DRESS were high CD4(+) and CD19(+) cell-count numbers in VE but low B-cell numbers in DRESS. This might be important for discriminating VE from DRESS, and the low B-cell count in early symptoms might be a useful predictor of DRESS development. (C) 2019 SEICAP. Published by Elsevier Espana, S.L.U. All rights reserved.Öğe Stevens-Johnson syndrome: a case report(Blackwell Publishing, 2008) Yazicioglu, M.; Yscan, B.; Turgut, B.; Yalcin, O.[Abstract Not Available]Öğe Stevens-Johnson syndrome: a case report [Letter](Elsevier Doyma Sl, 2009) Yazicioglu, M.; Iscan, B.; Turgut, B.; Yalcin, O.[Abstract Not Available]
